Literature DB >> 21792076

Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer.

V Shane Pankratz1, Zhifu Sun, Jeremiah Aakre, Yan Li, Cassandra Johnson, Yolanda I Garces, Marie C Aubry, Julian R Molina, Dennis A Wigle, Ping Yang.   

Abstract

INTRODUCTION: Studies from selected candidate genes suggest that single-nucleotide polymorphisms (SNPs) involved in glutathione metabolism, DNA repair, or inflammatory responses may affect overall survival (OS) in stages I to II or low-stage non-small cell lung cancer (LS-NSCLC); however, results are inconclusive. In this study, we took a systematic pathway-based approach to simultaneously evaluate the impact of genetic variation from these three pathways on OS after LS-NSCLC diagnosis.
METHODS: DNA from 647 patients with LS-NSCLC was genotyped for 480 SNPs (tag-SNPs) tagging 57 genes from the three candidate pathways. Associations of tag-SNPs with OS were assessed at the individual SNP and whole gene levels, adjusting for age, tumor stage, surgery type, and adjuvant therapy. The genotype combinations of the SNPs associated with OS were also estimated.
RESULTS: Among the 412 tag-SNPs that were successfully genotyped and passed quality assessments, 28 showed association with OS (p < 0.05). Two of the 28 were estimated to have less than a 20% chance of being false positives (rs3768490 in GSTM5: p = 1.32 × 10, q = 0.06; rs1729786 in ABCC4: p = 9.25 × 10, q = 0.20). Gene-based analysis suggested that in addition to GSTM5 and ABCC4, variation in two other genes, PTGS2 and GSTA2, was also associated with OS.
CONCLUSIONS: We describe further evidence that variations in genes involved in the glutathione and inflammatory response pathways are associated with OS in patients with LS-NSCLC. Further studies are warranted to verify our findings and elucidate their functional mechanisms and clinical utility leading to improved survival for patients with lung cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21792076      PMCID: PMC3158278          DOI: 10.1097/JTO.0b013e318223bf05

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  41 in total

1.  DNA repair: a double-edged sword.

Authors:  Q Wei; M L Frazier; B Levin
Journal:  J Natl Cancer Inst       Date:  2000-03-15       Impact factor: 13.506

2.  Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.

Authors:  Daniela F Giachino; Paolo Ghio; Silvia Regazzoni; Giorgia Mandrile; Silvia Novello; Giovanni Selvaggi; Dario Gregori; Mario DeMarchi; Giorgio V Scagliotti
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

3.  Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion.

Authors:  S Xu; Y Wang; B Roe; W R Pearson
Journal:  J Biol Chem       Date:  1998-02-06       Impact factor: 5.157

4.  Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

Authors:  Maria Rius; Johanna Hummel-Eisenbeiss; Alan F Hofmann; Dietrich Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-11-10       Impact factor: 4.052

5.  Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia.

Authors:  Marc Ansari; Géraldine Sauty; Malgorzata Labuda; Vincent Gagné; Caroline Laverdière; Albert Moghrabi; Daniel Sinnett; Maja Krajinovic
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113

6.  Isolation and analysis of the gene and cDNA for a human Mu class glutathione S-transferase, GSTM4.

Authors:  K E Comstock; K J Johnson; D Rifenbery; W D Henner
Journal:  J Biol Chem       Date:  1993-08-15       Impact factor: 5.157

7.  Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer.

Authors:  Daniele Campa; Shanbeh Zienolddiny; Valentina Maggini; Vidar Skaug; Aage Haugen; Federico Canzian
Journal:  Carcinogenesis       Date:  2003-11-06       Impact factor: 4.944

Review 8.  Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2).

Authors:  Ulrike Gradhand; Richard B Kim
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

9.  Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.

Authors:  Tomoyoshi Takenaka; Tokujiro Yano; Chikako Kiyohara; Naoko Miura; Hidenori Kouso; Taro Ohba; Takuro Kometani; Fumihiro Shoji; Ichiro Yoshino; Yoshihiko Maehara
Journal:  Lung Cancer       Date:  2010-01       Impact factor: 5.705

10.  The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).

Authors:  Mojca Strazisar; Vid Mlakar; Damjan Glavac
Journal:  Cell Mol Biol Lett       Date:  2009-02-23       Impact factor: 5.787

View more
  10 in total

1.  Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.

Authors:  Cassandra Johnson; Vernon S Pankratz; Ana I Velazquez; Jeremiah A Aakre; Charles L Loprinzi; Nathan P Staff; Anthony J Windebank; Ping Yang
Journal:  J Neurol Sci       Date:  2015-01-05       Impact factor: 3.181

2.  Lung cancer histology classification from CT images based on radiomics and deep learning models.

Authors:  Panagiotis Marentakis; Pantelis Karaiskos; Vassilis Kouloulias; Nikolaos Kelekis; Stylianos Argentos; Nikolaos Oikonomopoulos; Constantinos Loukas
Journal:  Med Biol Eng Comput       Date:  2021-01-07       Impact factor: 2.602

Review 3.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

4.  Genetic variations and patient-reported quality of life among patients with lung cancer.

Authors:  Jeff A Sloan; Mariza de Andrade; Paul Decker; Jason Wampfler; Curtis Oswold; Matthew Clark; Ping Yang
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

5.  Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.

Authors:  Md Siddiqul Islam; Mohammad Safiqul Islam; Salma Parvin; Maizbah Uddin Ahmed; Muhammad Shahdaat Bin Sayeed; Mir Muhammad Nasir Uddin; Syed Md Akram Hussain; Abul Hasnat
Journal:  Tumour Biol       Date:  2015-02-13

6.  Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.

Authors:  Liang Li; Daniel J Schaid; Brooke L Fridley; Krishna R Kalari; Gregory D Jenkins; Ryan P Abo; Anthony Batzler; Irene Moon; Linda Pelleymounter; Bruce W Eckloff; Eric D Wieben; Zhifu Sun; Ping Yang; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2012-02       Impact factor: 2.089

7.  Aberrant expression of GSTM5 in lung adenocarcinoma is associated with DNA hypermethylation and poor prognosis.

Authors:  Xuewei Hao; Jun Zhang; Guoyou Chen; Weiwei Cao; Hongyang Chen; Shuo Chen
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

8.  Synergistic association of PTGS2 and CYP2E1 genetic polymorphisms with lung cancer risk in northeastern Chinese.

Authors:  Shujie Guo; Xiaobo Li; Min Gao; Hong Kong; Yuqiong Li; Mingliang Gu; Xiaoqun Dong; Wenquan Niu
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

9.  A Panel of Genetic Polymorphism for the Prediction of Prognosis in Patients with Early Stage Non-Small Cell Lung Cancer after Surgical Resection.

Authors:  Shin Yup Lee; Jin Eun Choi; Hyo-Sung Jeon; Yi-Young Choi; Won Kee Lee; Eung Bae Lee; Hyun Cheol Lee; Hyo-Gyoung Kang; Seung Soo Yoo; Jaehee Lee; Seung Ick Cha; Chang Ho Kim; Myung Hoon Lee; Young Tae Kim; Sanghoon Jheon; Jae Yong Park
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

10.  Establishment of the Prognostic Index Reflecting Tumor Immune Microenvironment of Lung Adenocarcinoma Based on Metabolism-Related Genes.

Authors:  Jianguo Zhang; Jianzhong Zhang; Cheng Yuan; Yuan Luo; Yangyi Li; Panpan Dai; Wenjie Sun; Nannan Zhang; Jiangbo Ren; Junhong Zhang; Yan Gong; Conghua Xie
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.